A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Status: Recruiting
DFCI Protocol ID: 17-617

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Andrew Place, MD, PhD, Dana Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP, ctip@partners.org

Eligibility Criteria

Inclusion Criteria:

  -  Participants must have relapsed or refractory cancer.

  -  Participants must have adequate hepatic and kidney function.

  -  Participants less than or equal to 16 years of age must have performance status of
     Lansky greater than or equal to 50% and participants greater than 16 years of age must
     have performance status of Karnofsky greater than 50%.

  -  Participants with solid tumors (with the exception of neuroblastoma) must have
     adequate bone marrow function in Part 1.

  -  For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors
     must have evidence of BCL-2 expression.

Exclusion Criteria:

  -  Participants with primary brain tumors or disease metastatic to the brain.

  -  For participants with leukemia, has overt central nervous system (CNS) disease (CNS 3

  -  Participants who have received any of the following within the listed time frame,
     prior to the first dose of study drug

       -  Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days

       -  CAR-T infusion or other cellular therapy within 30 days

       -  Anticancer therapy including blinatumomab or chemotherapy, radiation therapy,
  targeted small molecule agents, investigational agents within 14 days or 5
  half-lives, whichever is shorter

       -  Steroid therapy for anti-neoplastic intent within 5 days

       -  Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)

  -  Participants who are less than 100 days post-transplant, or greater than or equal to
     100 days post-transplant with active graft versus host disease (GVHD), or are
     receiving immunosuppressant therapy within 7 days prior to first dose of study drug.

  -  Participants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG)

  -  Participants who have received the following within 7 days prior to the first dose of
     study drug:

       -  Strong and moderate Cytochrome P450 3A (CYP3A) inhibitors (Part 1 Dose

       -  Strong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort

  -  Participants who have not recovered from clinically significant adverse
     effect(s)/toxicity(s) of the previous therapy.

  -  Participants who have active, uncontrolled infections.

  -  Participants with malabsorption syndrome or any other condition that precludes enteral

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.